.jpg)
.png)
All
The ODYSSEY OUTCOMES trial results, announced today at the American College of Cardiology 67th Annual Scientific Sessions in Orlando, revealed the addition of alirocumab to maximally tolerated statin significantly reduced major adverse cardiovascular events (MACE) compared to those on maximally... more
The Foundation of the National Lipid Association (FNLA) supports patient and clinician educational, research, and community outreach activities that enhance and support the initiatives of the NLA in its efforts to reduce cardiovascular events and deaths related to abnormalities of cholesterol... more
Familial defective apolipoprotein B-100 (FDB) is an autosomal dominant disorder of lipid metabolism considered by international guidelines to be a genetically defined cause of familial hypercholesterolemia (FH).1–3 FDB arises from mutations in apolipoprotein B (apoB) affecting the affinity of apoB-... more
Pathogenicity of Lipoprotein (a) Lipoprotein(a) (Lp(a)) resembles an LDL-like lipoprotein with apolipoprotein(a) covalently bound with a disulfide link to apolipoprotein B on the particle surface. Lp(a)’s pro-inflammatory, pro-atherogenic, and pro-thrombotic properties have been linked by... more
Epidemiology The ever- increasing population of patients living after organ transplantation has added an important dimension to the specific management needs of these patients. One major area in this regard pertains to the effects of post-transplant immunosuppressive drugs on lipids and... more
Dr. Kevin Maki was interested in studying heart disease and diabetes from an early age. Seeing his father and father’s siblings suffer from cardiovascular disease influenced him to begin researching the causes of heart disease while he was still in high school. He quickly became convinced that it... more
Please fill out all form fields, everything is required for submission. Thank you for your participation in the NLA.
Thank you for joining the NLA's Connecting the Dots webcast. Select the appropriate certificate below. You can then type in your name and print or save a copy for your records. For questions related to this activity, contact ahicks@lipid.org.
Thank you! It will be an honor to serve as your next President of the NLA. I am looking forward to working with our Board of Directors in the continued growth of our organization to meet the educational and scientific needs of you and your patients. The NLA and the Foundation of the NLA have made... more
2026 #NLASessions Media Ambassador Program Program Overview The 2026 #NLASessions Media Ambassador Program empowers NLA's next generation of lipidologists — fellows-in-training, residents, associate members, and LSP recipients — to amplify NLA's mission, grow our digital presence, and bring... more